Analysis and Perspectives

Oct 16, 2023

Rare eye diseases can pose burden on patients. Top rare eye diseases are Stargardt Disease, Retinitis Pigmentosa, LHON, Retinoblastoma, LSCD

Oct 11, 2023

Immunomodulators are reshaping the healthcare market outlook with their diverse benefits and applications, thereby improving health outcomes.

Oct 09, 2023

FDA approved Rivfloza for primary hyperoxaluria treatment. This announcement comes as Novo continues to make strides in field of RNAi drugs.

Oct 06, 2023

Since scopolamine transdermal patch FDA approval, no other treatments approved in US for nausea and vomiting induced by motion sickness.

Oct 04, 2023

Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...

Sep 29, 2023

With rise of gene therapy and other innovative therapeutic approaches, we experience profound change in Netherton syndrome treatment space.

Sep 22, 2023

FDA approved GSK's momelotinib, marketed under name Ojjaara, for management of myelofibrosis in adult patients suffering from anemia.

Sep 20, 2023

Sleep Aids Market: Examining Cutting-Edge Technologies and Scientific Breakthroughs Sleep can be burdensome when it disrupts daily routines, requires a significant time commitment, and is marred by sleep disorders or disturbances that affect overall well-being. In today's fast-paced world, where stress, anxiety,...

Sep 18, 2023

Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United States have Huntington’s disease, and another 200,000 are at risk of developing the condition. As per DelveInsight analy...

Sep 15, 2023

The dynamics of the myelodysplastic syndrome treatment market are anticipated to change in the coming years owing to the emerging therapies.